CA
NZ
UK
AU
IND
US
…
NuGen Medical Devices Inc., a specialty medical device company, develops and commercializes novel drug delivery technologies in Europe, Asia, North America, Canada, and internationally. The company offers needle-free injection devices and systems for the administration of subcutaneous medication for various fields, including diabetes, Vaccines, Veterinary, Home healthcare, and others. It also provides InsuJet that focuses on servicing the diabetic community; and V5, V6, V7, and V8 InsuJet injectors. NuGen Medical Devices Inc. is headquartered in Toronto, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
NuGen Medical Devices Inc appears to be a Canada-listed medical device company with limited public disclosures about its products or commercial stage. Its long-term growth may depend on successful product development, regulatory approvals and commercial adoption, and investors may find exposure to healthcare innovation and potential upside if technologies reach market.
Key risks include limited public information, early-stage development and likely need for additional financing, regulatory and clinical trial uncertainty, thin trading liquidity and execution risk.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -5.22M | -9.33M | -5.57M | -7.10M | -3.66M |
| Net income | -5.23M | -9.36M | -5.58M | -7.11M | -3.67M |
| Selling general administrative | 5.03M | 7.52M | 4.24M | 7.76M | 2.65M |
| Gross profit | 0.52M | 0.16M | 0.10M | 0.09M | 0.03M |
| Reconciled depreciation | 0.65M | 0.69M | 0.65M | 0.79M | 0.40M |
| Ebit | - | - | - | -5.79M | -2.59M |
| Ebitda | - | - | - | -5.09M | -2.59M |
| Operating income | -5.16M | -8.04M | -4.79M | -7.67M | -2.61M |
| Interest expense | 1.67M | 1.24M | 1.01M | 1.22M | 0.67M |
| Tax provision | 0.01M | 0.03M | 0.00M | 0.00M | 0.01M |
| Interest income | - | - | - | 0.02M | 0.02M |
| Net interest income | -1.85M | -1.24M | -0.86M | -1.20M | -0.89M |
| Income tax expense | - | - | - | - | 0.01M |
| Total revenue | 1.01M | 0.33M | 0.15M | 0.14M | 0.05M |
| Total operating expenses | 6.17M | 8.37M | 4.94M | 7.81M | 2.66M |
| Cost of revenue | 0.49M | 0.17M | 0.05M | 0.05M | 0.01M |
| Total other income expense net | 1.79M | -0.05M | 0.07M | 1.76M | -0.16M |
| Net income from continuing ops | -5.23M | -9.36M | -5.58M | -7.11M | -3.67M |
| Net income applicable to common shares | - | - | - | - | -3.67M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 12.89M | 6.95M | 6.85M | 8.84M | 14.56M |
| Intangible assets | 3.36M | 3.89M | 4.45M | 5.02M | 6.26M |
| Other current assets | - | - | - | - | 6.01M |
| Total liab | 18.57M | 9.01M | 9.11M | 7.19M | 15.25M |
| Total stockholder equity | -5.67M | -2.06M | -2.26M | 1.66M | -0.69M |
| Other current liab | - | - | - | 0.01M | 6.01M |
| Common stock | - | - | - | - | 6.81M |
| Capital stock | 23.22M | 21.36M | 15.07M | 14.19M | 6.81M |
| Retained earnings | -34.37M | -29.30M | -20.61M | -15.81M | -8.70M |
| Other liab | - | - | - | - | 0.92M |
| Good will | 1.73M | 1.69M | 1.67M | 1.67M | 1.81M |
| Cash | 6.95M | 0.46M | 0.13M | 1.75M | 0.27M |
| Total current liabilities | 1.34M | 3.29M | 1.73M | 1.23M | 9.75M |
| Net debt | 10.86M | 7.39M | 7.11M | 4.18M | 7.22M |
| Short long term debt | 0.57M | 2.14M | 0.08M | 0.33M | 2.91M |
| Other stockholder equity | - | - | - | - | 1.20M |
| Property plant equipment | - | - | - | - | 0.03M |
| Total current assets | 7.80M | 1.33M | 0.57M | 2.15M | 6.47M |
| Net tangible assets | - | - | - | - | -8.76M |
| Net receivables | 0.10M | 0.02M | 0.01M | 0.01M | 0.15M |
| Long term debt | 17.23M | 5.72M | 7.16M | 5.61M | 4.58M |
| Inventory | 0.32M | 0.21M | 0.08M | 0.01M | 0.01M |
| Accounts payable | 0.67M | 0.97M | 1.44M | 0.88M | 0.82M |
| Non current assets total | 5.09M | 5.62M | 6.28M | 6.70M | 8.09M |
| Capital lease obligations | 0.00M | 0.03M | 0.16M | - | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -0.01M | -0.05M | -0.00M | 0.00M | 0.05M |
| Change to liabilities | - | - | - | 0.00M | 0.44M |
| Total cashflows from investing activities | - | - | - | - | 0.05M |
| Net borrowings | 9.97M | 5.71M | -0.08M | 0.07M | 0.73M |
| Total cash from financing activities | 11.21M | 7.10M | 4.85M | 5.58M | 1.62M |
| Change to operating activities | - | - | - | - | 0.10M |
| Net income | -5.23M | -9.36M | -5.58M | -7.11M | -3.67M |
| Change in cash | 6.48M | 0.33M | -0.00M | 1.47M | 0.27M |
| Begin period cash flow | 0.46M | 0.13M | 0.20M | 0.28M | 0.00M |
| End period cash flow | 6.95M | 0.46M | 0.16M | 1.75M | 0.28M |
| Total cash from operating activities | -4.71M | -6.71M | -4.88M | -4.10M | -1.39M |
| Issuance of capital stock | - | 6.58M | 4.87M | 5.51M | 0.65M |
| Depreciation | 0.65M | 0.69M | 0.73M | 0.63M | 0.38M |
| Change to inventory | -0.11M | -0.13M | -0.01M | -0.00M | 0.00M |
| Change to account receivables | - | - | - | - | 0.01M |
| Change to netincome | - | - | - | 2.61M | 1.24M |
| Capital expenditures | 0.01M | 0.00M | 0.00M | 0.00M | 0.01M |
| Change in working capital | -0.34M | -0.73M | -1.73M | -0.23M | 0.66M |
| Stock based compensation | 0.09M | 1.36M | 1.59M | 1.31M | 0.00M |
| Other non cash items | 2.15M | 1.23M | 2.25M | 1.15M | 1.21M |
| Free cash flow | -4.72M | -6.72M | -4.89M | -4.10M | -1.40M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NGMD NuGen Medical Devices Inc |
- -% |
0.01 | - | - | 11.56 | 9.71 | 35.35 | 14.65 |
| TLT Theralase Technologies Inc. |
0.01 2.78% |
0.18 | - | - | 90.07 | 82.51 | 90.31 | -12.06 |
| CNVI Conavi Medical Corp. |
-0.01 4.55% |
0.10 | - | - | 66.65 | - | 95.30 | - |
| PINK Perimeter Medical Imaging AI Inc |
- -% |
0.18 | 4.13 | - | 18.78 | 11.34 | 20.22 | -2.55 |
| CHER Cheelcare Inc. |
- -% |
1.25 | - | - | 20.92 | 106.42 | 21.26 | - |
NuGen Medical Devices Inc., a specialty medical device company, develops and commercializes novel drug delivery technologies in Europe, Asia, North America, Canada, and internationally. The company offers needle-free injection devices and systems for the administration of subcutaneous medication for various fields, including diabetes, Vaccines, Veterinary, Home healthcare, and others. It also provides InsuJet that focuses on servicing the diabetic community; and V5, V6, V7, and V8 InsuJet injectors. NuGen Medical Devices Inc. is headquartered in Toronto, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael Wright | Pres, CEO & Director | 1967 |
| Ms. Veronique Laberge | CFO & Sec. | 1983 |
| Mr. Nicky Canton | Chief Operating Officer | 1983 |
| Ms. Elisha Dillon | Head of Global Sales & Strategic Partnerships | NA |
| Mr. Anthony Di Benedetto | Executive Chairman | 1972 |
| Mr. Ian Heynen | Chief Executive Officer | NA |
| Mr. Richard Buzbuzian BA | President & Director | 1971 |
| Ms. Veronique Laberge B.A., CPA | CFO & Secretary | 1983 |
| Mr. Nicky Canton | Executive VP & COO | 1984 |
| Ms. Karen Dunlap | Interim Chief Customer Officer & Director | 1948 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+2.10%
Communication Services
+1.48%
Consumer Cyclical
+2.12%
Consumer Defensive
+1.59%
Energy
-2.52%
Financial Services
+1.11%
Financials
-6.05%
Healthcare
+2.12%
Industrials
-0.12%
Real Estate
+1.25%
Technology
-0.07%
Utilities
+0.57%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...